The modulation of RAS may play a role in the reduced GFAP immunoreactivity, as documented earlier, where blocking AT1R with losartan [92] or inhibiting ACE with perindopril [93] in models of AD have inhibited this astrogliosis marker. Here, GFAP is linked to Alzheimer disease.